Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...

Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial and operational results on March 14 ...

Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of d, its lead investigational allogeneic T-cell immunotherapy, acute myeloid ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...